Novel Inhibitors of Cholesterol Degradation in Mycobacterium tuberculosis Reveal How the Bacterium’s Metabolism Is Constrained by the Intracellular Environment

• Brian C. VanderVen ,

  * E-mail: bcv8@cornell.edu

  Affiliation Department of Microbiology and Immunology, Cornell University, Ithaca, New York, United States of America

  ⨯
• Ruth J. Fahey,

  Affiliation Department of Microbiology and Immunology, Cornell University, Ithaca, New York, United States of America

  ⨯
• Wonsik Lee,

  Affiliation Department of Microbiology and Immunology, Cornell University, Ithaca, New York, United States of America

  ⨯
• Yancheng Liu,

  Affiliation Department of Microbiology and Immunology, Cornell University, Ithaca, New York, United States of America

  ⨯
• Robert B. Abramovitch,

  Affiliation Department of Microbiology and Immunology, Cornell University, Ithaca, New York, United States of America

  ⨯
• Christine Memmott,

  Affiliation Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, United States of America

  ⨯
• Adam M. Crowe,

  Affiliation Departments of Microbiology and Biochemistry, University of British Columbia, Vancouver, British Columbia, Canada

  ⨯
• Lindsay D. Eltis,

  Affiliation Departments of Microbiology and Biochemistry, University of British Columbia, Vancouver, British Columbia, Canada

  ⨯
• Emanuele Perola,

  Affiliation Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, United States of America

  ⨯
• David D. Deininger,

  Affiliation Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, United States of America

  ⨯
• Tiansheng Wang,

  Affiliation Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, United States of America

  ⨯
• Christopher P. Locher,

  Affiliation Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, United States of America

  ⨯
• David G. Russell

  Affiliation Department of Microbiology and Immunology, Cornell University, Ithaca, New York, United States of America

  ⨯